胎盘转运体介导的药物相互作用与子代先天畸形
基于1996–2014年国家药物与妊娠数据库的出生队列研究,纳入单胎妊娠,比较P-gp/BCRP联合用药、单药、非P-gp/BCRP联合用药及未暴露组的先天畸形风险。P-gp/BCRP联合用药组先天畸形患病率5.5%,高于单药组4.7%(OR 1.13;95%CI 1.05–1.21)、非P-gp/BCRP联合用药组4.9%(OR 1.14;95%CI 1.06–1.22)和未暴露组4.2%(OR 1.23;95%CI 1.15–1.31)。结果提示胎盘转运体介导的药物相互作用在致畸中可能起作用。
要点
- 孕前1个月或早孕期同时暴露于P-gp/BCRP底物或抑制剂者,先天畸形风险升高。
- P-gp/BCRP联合用药组畸形率5.5%,高于单药组4.7%和未暴露组4.2%。
- 临床应关注妊娠期P-gp/BCRP联合用药的潜在致畸风险。
核心结论
- P-gp/BCRP联合用药与子代先天畸形风险升高相关,提示胎盘转运体介导的药物相互作用可能参与致畸过程。
研究设计与样本
- 基于1996–2014年国家药物与妊娠数据库的出生队列研究,链接医学出生登记、人工流产登记、畸形登记和报销药物购买登记。
- 纳入单胎妊娠(活产或因胎儿畸形选择性终止),排除已知致畸物暴露。
- 暴露组:P-gp/BCRP联合用药n=21 186;P-gp/BCRP单药n=97 906;非P-gp/BCRP联合用药n=78 636;未暴露n=728 870。
- 采用logistic回归调整多个混杂因素,分析暴露组与重大先天畸形的关联。
主要发现
- P-gp/BCRP联合用药组先天畸形患病率5.5%,高于单药组4.7%(OR 1.13;95%CI 1.05–1.21)。
- P-gp/BCRP联合用药组先天畸形患病率高于非P-gp/BCRP联合用药组4.9%(OR 1.14;95%CI 1.06–1.22)。
- P-gp/BCRP联合用药组先天畸形患病率高于未暴露组4.2%(OR 1.23;95%CI 1.15–1.31)。
临床怎么用
- 临床在孕前及早孕期应评估P-gp/BCRP底物或抑制剂的联合用药方案,关注潜在致畸风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are efflux transporters expressed in the placenta, limiting their substrates from reaching the foetus. Our aim was to investigate if concomitant prenatal exposure to several substrates or inhibitors of these transporters increases the risk of congenital anomalies. METHODS: The national Drugs and Pregnancy database, years 1996-2014, was utilized in this population-based birth cohort study. In the database, the Medical Birth Register, the Register on Induced Abortions, the Malformation register and the Register on Reimbursed Drug Purchases have been linked. The University of Washington Metabolism and Transport Drug Interaction Database was used to identify substrates and inhibitors of P-gp and BCRP. We included singleton pregnancies ending in birth or elective termination of pregnancy due to foetal anomaly. Known teratogens were excluded. We identified women exposed 1 month before pregnancy or during the first trimester to P-gp/BCRP polytherapy (n = 21 186); P-gp/breast cancer resistance protein monotherapy (n = 97 906); non-P-gp/BCRP polytherapy (n = 78 636); and unexposed (n = 728 870). We investigated the association between the exposure groups and major congenital anomalies using logistic regression adjusting for several confounders. RESULTS: The prevalence of congenital anomalies was higher in the P-gp/BCRP polytherapy group (5.5%) compared to the P-gp/BCRP monotherapy (4.7%, OR 1.13; 95% CI 1.05-1.21), the non-P-gp/BCRP polytherapy (4.9%, OR 1.14; 95% CI 1.06-1.22), and to the unexposed groups (4.2%, OR 1.23; 95% CI 1.15-1.31). CONCLUSION: The results suggest a role of placental transporter-mediated drug interactions in teratogenesis.
引用
- Ellfolk M, Tornio A, Niemi M, et al. Placental transporter-mediated drug interactions and offspring congenital anomalies. Br J Clin Pharmacol. 2020. PMID: 31823387. doi:10.1111/bcp.14191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。